SWIFT - Do you have Moderate to Severely Active UC?

The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo.

The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.

Category
Inflammatory Bowel Disease All Clinical Trials
Trial status
Recruiting
Trial phase
Phase 2 Drug Trial
Early stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
Registry listing
NCT06290934
ERM Project ID
105372

Trial contact details

Contact person
Sharyn Grossman
Email
ibdtrials.coordinator@mater.org.au
Phone
07 3163 8195

What you need to know

Who can take part?

To participate, you must:

Be 18-75 years of age
Have UC diagnosis confirmed by endoscopy & histology
Have had previous treatment for UC (confirm requirements with study team)
Have test results within expected ranges
Not have an additional condition that may impact your UC treatment
Not have previously had Vedolizumab
Not be taking any medications that may impact the results (study team will confirm)
Not have surgery planned
Not be pregnant or planning pregnancy